Welcome to the international HTA database

Showing [24104 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2024	NIHR Health Technology Assessment programme	Behavioural interventions to treat anxiety in adults with autism and moderate to severe intellectual disabilities: the BEAMS-ID feasibility study
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: helicobacter pylori - diagnosis, optimal treatment and follow-up]
2024	Agency for Care Effectiveness (ACE)	Nerivio for the acute and preventive treatment of migraine
2024	Health Information and Quality Authority (HIQA)	Health technology assessment of birth cohort testing for hepatitis C: a short report update
2024	NIHR Health and Social Care Delivery Program	The use of locum doctors in the NHS: understanding and improving the quality and safety of care
2024	NIHR Health Technology Assessment programme	Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: clozapine blood level testing by immunoassay]
2024	Agency for Care Effectiveness (ACE)	CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: relevance of preoperative consultation and testing for low-risk elective surgery in people aged 16 and over]
2024	NIHR Health Services and Delivery Research programme	Patient buy-in to social prescribing through link workers as part of person-centred care: a realist evaluation
2024	NIHR Health Technology Assessment programme	Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Blood determination of a panel of anti-tuberculosis drugs using a multiplex approach by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) in the context of clinical pharmacometrics]
2024	Agency for Care Effectiveness (ACE)	Canvas Dx to aid the diagnosis of autism spectrum disorder
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, gating mutation, heterozygous) – Benefit assessment according to §35a]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Newsletter: overview of mobile applications in health and social services]
2024	NIHR Health Technology Assessment programme	Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis
2024	Agency for Care Effectiveness (ACE)	RelieVRx for the treatment of chronic lower back pain
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cannabidiol (Dravet syndrome) – Benefit assessment according to §35a Social Code Book V]
2024	National Institute for Health and Care Excellence (NICE)	Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal). NICE technology appraisal guidance 965
2024	NIHR Health Technology Assessment programme	Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews
2024	NIHR Health and Social Care Delivery Program	Implementing an artificial intelligence command centre in the NHS: a mixed-methods study
2024	Agency for Care Effectiveness (ACE)	Organ Care System (OCS) Heart System for heart transplantation of marginal brain-death donor hearts or circulatory-death donor hearts
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cannabidiol (tuberous sclerosis) – Benefit assessment according to §35a Social Code Book V]
2024	National Institute for Health and Care Excellence (NICE)	Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 964
2024	NIHR Health Services and Delivery Research programme	Routine outcomes to investigate differences between ethnic minorities and White British people presenting to emergency services for injury: the stakeholder consultation
2024	NIHR Health and Social Care Delivery Program	Using the Recommended Summary Plan for Emergency Care and Treatment in Primary Care: a mixed methods study
2024	Agency for Care Effectiveness (ACE)	KidneyIntelX for patients with diabetic kidney disease
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024	National Institute for Health and Care Excellence (NICE)	Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 963
2024	Penn Medicine Center for Evidence-based Practice (CEP)	Hyperbaric oxygen therapy for injury recovery among athletes
2024	NIHR Health Services and Delivery Research programme	Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024	Agency for Care Effectiveness (ACE)	Oxevision for vision-based patient monitoring and management in mental health wards
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book]
2024	National Institute for Health and Care Excellence (NICE)	Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 962
2024	NIHR Health Technology Assessment programme	Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024	NIHR Health and Social Care Delivery Program	What happens between first symptoms and first acute exacerbation of COPD – observational study of routine data and patient survey
2024	Agency for Care Effectiveness (ACE)	FEops HEARTguide for procedure planning in patients needing transcatheter left atrial appendage occlusion (LAAO) device
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, RF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024	National Institute for Health and Care Excellence (NICE)	Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal). NICE technology appraisal guidance 961
2024	NIHR Health Technology Assessment programme	The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024	NIHR Health and Social Care Delivery Program	Pathways to specialist community perinatal mental health services: a two-site longitudinal retrospective service evaluation
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, other/unknown mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024	National Institute for Health and Care Excellence (NICE)	Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2024	NIHR Health Technology Assessment programme	Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2024	Norwegian Institute of Public Health (NIPH)	[Robot–assisted hysterectomy for benign conditions: A rapid health technology assessment]
2024	Institute for Clinical and Economic Review (ICER)	Sotatercept for pulmonary arterial hypertension
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024	National Institute for Health and Care Excellence (NICE)	Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis. NICE technology appraisal guidance 959
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: blood quantification of fludarabine by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)]
2024	Institute for Clinical and Economic Review (ICER)	KarXT for schizophrenia
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tebentafusp (uveal melanoma) – Benefit assessment according to §35a Social Code Book]
2024	National Institute for Health and Care Excellence (NICE)	Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2024	NIHR Health Technology Assessment programme	Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
2024	Institute for Clinical and Economic Review (ICER)	Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Patisiran (hereditary transthyretin-mediated amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V]
2024	National Institute for Health and Care Excellence (NICE)	Momelotinib for treating myelofibrosis-related splenomegaly or symptoms. NICE technology appraisal guidance 957
2024	NIHR Health Services and Delivery Research programme	Consequences of how third sector organisations are commissioned in the NHS and local authorities in England: a mixed-methods study
2024	NIHR Health and Social Care Delivery Program	Understanding and improving the quality of primary care for people in prison: a mixed-methods study
2024	Institute for Clinical and Economic Review (ICER)	Midomafetamine-assisted psychotherapy for post-traumatic stress disorder
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024	National Institute for Health and Care Excellence (NICE)	Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over. NICE technology appraisal guidance 956
2024	Penn Medicine Center for Evidence-based Practice (CEP)	Impact of workforce racial and ethnic diversity on patient health and healthcare outcomes
2024	NIHR Health and Social Care Delivery Program	Challenges and guidance for implementing social distancing for COVID-19 in care homes: a mixed methods rapid review
2024	Institute for Clinical and Economic Review (ICER)	Ensifentrine for the treatment of chronic obstructive pulmonary disease: effectiveness and value
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Early detection of vitamin B12 deficiency and other target diseases (homocystinuria, propionic acidaemia and methylmalonic acidaemia) in extended newborn screening (ENS)]
2024	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 955
2024	NIHR Health Technology Assessment programme	MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis
2024	NIHR Health and Social Care Delivery Program	The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2024	Institute for Clinical and Economic Review (ICER)	Imetelstat for anemia in myelodysplastic syndrome: effectiveness and value
2024	NIHR Health Services and Delivery Research programme	Practices of falls risk assessment and prevention in acute hospital settings: a realist investigation
2024	National Institute for Health and Care Excellence (NICE)	Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 954
2024	NIHR Health Technology Assessment programme	Antidepressants for pain management in adults with chronic pain: a network meta-analysis
2024	Health Sciences Institute in Aragon (IACS)	[Portable external trigeminal nerve stimulator (eTNS) device for the treatment of migraine headaches]
2024	Institute for Clinical and Economic Review (ICER)	Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
2024	NIHR Health Technology Assessment programme	Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysis
2024	National Institute for Health and Care Excellence (NICE)	Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema. NICE technology appraisal guidance 953
2024	NIHR Health Technology Assessment programme	Specific phobias in children with moderate to severe intellectual disabilities: SPIRIT, an adaptation and feasibility study
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: prolotherapy's efficacy and safety in the treatment of chronic musculoskeletal pain]
2024	Institute for Clinical and Economic Review (ICER)	Tabelecleucel for epstein-barr virus positive post-transplant lymphoproliferative disease: effectiveness and value
2024	NIHR Health Technology Assessment programme	A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)
2024	National Institute for Health and Care Excellence (NICE)	Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE technology appraisal guidance 952
2024	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: indolent systemic mastocytosis (ISM))]
2024	Institute for Clinical and Economic Review (ICER)	Managing the challenges of paying for gene therapy: strategies for market action and policy reform
2024	NIHR Health Technology Assessment programme	Lower urinary tract symptoms in men: the TRIUMPH cluster RCT
2024	National Institute for Health and Care Excellence (NICE)	Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 951
2024	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Momelotinib (myelofibrosis)]
2024	Institute for Clinical and Economic Review (ICER)	Unsupported price increase report: unsupported price increases occurring in 2023
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Exposure therapy with virtual reality in adults with specific phobia]
2024	NIHR Health Technology Assessment programme	Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT
2024	National Institute for Health and Care Excellence (NICE)	Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. NICE technology appraisal guidance 950
2024	Norwegian Medical Products Agency (NOMA)	[Interferon gamma-1b for treatment of Friedreich’s ataxia: a health technology assessment without submitted documentation]
2024	Institute for Clinical and Economic Review (ICER)	Assessment of barriers to fair access
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Update]
2024	NIHR Health Technology Assessment programme	Surgical versus non-surgical management of lateral compression type-1 pelvic fracture in adults 60 years and older: the L1FE RCT
2024	National Institute for Health and Care Excellence (NICE)	Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over. NICE technology appraisal guidance 949
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of deep brain stimulation in severe and treatment-resistant obsessive-compulsive disorder]
2024	National Institute for Health and Care Excellence (NICE)	Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments. NICE technology appraisal guidance 948
2024	National Institute for Health and Care Excellence (NICE)	Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 947
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Percutaneous treatment for moderate to severe mitral valve insufficiency]